secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950103-24-006675
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024
--------------------------------------------------------------------------------

- Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.
- Cash, equivalents, and short-term investments $44.8M; evaluating financing options to strengthen balance sheet.
- PRGN-2012 pivotal Phase 2 data as late-breaking oral at ASCO June 3; rolling BLA submission expected H2 2024.
- Commercial readiness activities underway for potential PRGN-2012 launch in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324006675/0000950103-24-006675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324006675/dp211199_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-006675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer